Policy & Regulation
BrainStorm elects Jerold Chun (MD PhD) as chair of new SAB
12 March 2018 -

Adult stem cell therapeutics company BrainStorm Cell Therapeutics Inc (NASDAQ:BCLI) reported on Friday the appointment of Jerold Chun, MD, PhD as chair of the newly formed Scientific Advisory Board (SAB).

The company stated the SAB will be composed of renowned scientists and clinical experts that will advise its management team on scientific matters, research, clinical trials as well as drug development.

Currently, Dr Chun is the professor and the senior vice president of Neuroscience Drug Discovery at Sanford Burnham Prebys Medical Discovery Institute as well as leads a team of 25 researchers in the study of genomic mosaicism (DNA sequence variation in brain cells) and lysophospholipid receptor signaling to understand and develop drug treatments for Alzheimer's disease, multiple sclerosis, and hydrocephalus.

Previously, Dr Chun was a professor at The Scripps Research Institute and the University of California San Diego School of Medicine as well as head of the Department of Molecular Neuroscience at Merck Research Laboratories.

According to the company, Dr Chun has identified the first lysophospholipid receptor (1996), first to demonstrate genomic mosaicism in the brain (2001) and its alteration in Alzheimer's disease (2015). He is the recipient of over a dozen awards as well as has published ~300 scientific articles and three patents.